RECRUITINGOBSERVATIONAL
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Prospective Observational Study of Peritoneal Surface Malignancies (PSM) - Characterization, Models and Treatment Strategies.
About This Trial
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).
Who May Be Eligible (Plain English)
Who May Qualify:
- age \> 18 years
- confirmed diagnosis of peritoneal surface malignancy
- candidate for CRS-HIPEC
- written willing to sign a consent form
Who Should NOT Join This Trial:
- none
Approximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* age \> 18 years
* confirmed diagnosis of peritoneal surface malignancy
* candidate for CRS-HIPEC
* written informed consent
Exclusion Criteria:
* none
Approximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.
Treatments Being Tested
OTHER
Observational study.
Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor. HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease.
Locations (1)
The Norwegian Radium Hospital
Oslo, Norway